7 known cases. View patent page →
Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.
Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.
Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.
Antitrust action against Celgene; patents listed: 8,288,415; 8,315,886; 8,404,717. Assigned to Judge Esther Salas and Magistrate Michael A. Hammer. No termination date listed as of Feb. 19, 2026.
Celgene sued Hikma Pharmaceuticals International over generic lenalidomide; the asserted patents included the '784 patent and eight other patents. The case was terminated on 2019-09-18.
Celgene sued Lotus and Alvogen in D.N.J. asserting a portfolio including US 8,626,531. The court bifurcated and stayed claims as to several patents, and a consent judgment/injunction was entered; the case terminated Sept. 5, 2019.
Celgene action against Lotus and Alvogen over lenalidomide ANDA No. 210480. The narrative states the '018 patent was not listed among the patents challenged; the Rule 12(c) challenge involved the REMS patents '720, '977, '784, '886 and '531. The motion for judgment on the pleadings was denied without prejudice on December 14, 2018.